# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:PSTX) with a Buy and maintains $20 price t...
Promising early data suggest patients with relapsed/refractory multiple myeloma who progressed after prior BCMA-targeted therap...
Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an ...
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.